drugset / Trial / NCT03001453
Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to compare two medications currently injected intra-operatively to help decrease pain after surgery in patients undergoing a primary total hip replacement (THR). The two medications are Exparel® (bupivacaine liposome injectable suspension) plus bupivacaine with epinephrine versus bupivacaine with epinephrine. This study is looking to see if one medication works better than the other in managing post-operative pain after THR. The study hypothesis is that Exparel® plus bupivacaine with epinephrine will demonstrate better pain management in THR patients post-operatively. Both medications are FDA-approved for post-operative analgesia.
Timeline
- Start
- 2014-04
- Primary completion
- 2016-03
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupivacaine | Other / unclassified | 0.25 % | Other |
| Comparator | Bupivacaine | Other / unclassified | 40 ml | Other |
| Comparator | Bupivacaine | Other / unclassified | 60 ml | Other |
| Comparator | Bupivacaine | Other / unclassified | 266 mg | Other |